关键词: 野生型, 阿帕替尼, 非小细胞肺癌, 中医辨证

Abstract: ［Abstract］ Objective To evaluate the efficacy and adverse reaction of the chemotherapy by apatinib or apatinib combined with traditional Chinese medicine in treating with advanced NSCLC. Methods This was a prospective study from Jan 2017 to Sep 2018， and 59 patients with a confirmed diagnosis of stageⅢb?ⅣNSCLC. Among them，31 patients receive treatment of Apatinib alone （control group）， 28 patients receive combined treatment of TCM and Apatinib （treatment group）. Results 1. Comparison of recent objective efficacy： The ORR （14.29%） and DCR （60.71%） of the treatment group were lower than the ORR （19.35%） and DCR （64.52%） of the control group， but there were no significant difference between the two group （P>0.05）. Comparison of the survival time： The mPFS was 3.33 months in treatment group and 3.0 in control group， and there was no significant difference between the groups （P>0.05）. The MST in the treatment group was 5.17 months， and the control group was 4.9 months （P>0.05 when compared between two group）. 2. Comparison of the side effect rate and safety： The rate of hypertension， proteinuria and bone marrow suppression in the treatment group was lower than that of the control group， and the difference of proteinuria between the groups was statistically significant （P<0.05）. Conclusion Compared with apatinib， Apatinib combine with TCM has the same efficacy in treatment of advanced non?small?cell lung cancer. Apatinib combine with TCM can antagonize the toxic and side effects caused by apatinib， improve the tolerance of patients and improve the quality of life of patients.

Key words: apatinib, wild type, traditional Chinese medicine, advanced NSCLC